![]() ![]() The anticholesterol drug Lipitor has been Of atorvastatin and ziprasidone are already available in the U.S. Generic through Wyeth, a company it acquired in 2009. Pfizer will continue to manufacture Protonix as well as an authorized Resulting in a halt to generic manufacture and sale by Teva and Sun. These generic manufacturersĬlaimed that the original Protonix patent was invalid, but a courtĮventually ruled that the original patent for Protonix was indeed valid, Result of the launch of generic versions of pantoprazole by Teva and Protonix earned Pfizer more than $1.9 billion, but these revenues hadįallen to $480 million by 2010. Gastroesophageal reflux disease and other gastric acid hypersecretoryĭiseases, with an estimated cost of up to $173 per month. Protonix, a proton pump inhibitor, is used to treat (pantoprazole) and Geodon (ziprasidone), will all have lost patent Lipitor, Protonix, and the Pfizer Product LineĤ2% of Pfizer’s pharmaceutical revenue, including Lipitor, Protonix 1-6 Some notable drug patent expirations and the associated financial impact for their manufacturers are presented below. Protection for Pfizer’s Viagra (sildenafil). (zoledronic acid), its bisphosphonate drug, and its Diovan (valsartan),Īn antihypertensive, both expire in 2012, as does the first patent Lexapro (escitalopram) also expire in 2012. (rosiglitazone) and Forest Laboratories’ patent on the antidepressant GlaxoSmithKline’s (GSK) patent on the diabetes drug Avandia Well as its migraine medication, Maxalt (rizatriptan), in 2012. Merck loses its top-selling asthma drug, Singulair (montelukast), as (rosuvastatin) and its asthma drug Symbicort (budesonide/formoterol). In 2012 is AstraZeneca’s cholesterol-lowering drug Crestor Takeda) for type 2 diabetes the fertility drug Follistim (follitropinīeta injection, Organon) and the HIV/AIDs drug Viramune (nevira-pine, Spray for precocious puberty and endometriosis Actos (pioglitazone, Wallace) antihistamine nasal spray Synarel (nafarelin, Roche) nasal Other patents expiring in 2011 included Astelin (azelastine, Pfizer lost the glaucoma drug Xalatan (latanoprost ophthalmic In addition to the drugs mentioned above, in 2011īristol-Myers/Sanofi-Aventis lost exclusivity for Avapro (irbesartan),Īn angiotensin II receptor antagonist for treatment of hypertension, and Number of widely used drugs, including Advair (fluticasone propionateĪnd salmeterol), Levaquin (levofloxacin), Cozaar (losartan), and ![]() 2,3 Although the generic industry willīenefit in the short term, it will also see a slowdown in revenue growthĪfter 2015 because fewer branded blockbusters will be coming off patent The products at prices reported to average about 30% of the price of theīrand-name originals. 2,3 When patents expire, generic makers offer Protection can result in high profits, with gross profit marginsĮxceeding 90%. Once a drug enters the market, however, patent Get a product to market before as much as half of that period hasĪlready elapsed. Granted 20 years of patent protection, although companies often do not 2,3įor consumers, the savings from generics can be substantial. Once drugs lose patent protection, lower-price generics quickly siphon off as much as 90% of their sales. 1-5 Selected drugs whose patents have expired or will expire over the next several years are shown in TABLE 1. With patents on many so-calledīlockbuster drugs about to expire, an estimated $250 billion in sales isĪt risk between now and 2015. 6 That figure represents approximately 50% of theĬompanies’ combined U.S. Top drug companies’ annual sales in the United States between 2007 andĢ012 alone, as more than three dozen drugs lose patent protection during Furthermore, it isĮstimated that generic competition will have eroded $67 billion from To increase to more than $30 billion in annual sales. 1-5 In total, patents on drugs worth $12īillion expired by the end of 2011, and in 2012 that figure is expected Combined, these four drugs accounted for more than $7īillion in sales. Major drugs-Lipitor (atorvastatin), Caduet (amlodipine/atorvastatin),Īnd Solodyn (minocycline extended release tablet)-lost patent Paving the way for lower-priced generics. Industry will experience patent expirations over the next 5 years, Number of top-selling drugs in the history of the pharmaceutical ![]() History, a phenomenon referred to as the “patent cliff.” A significant Industry faced one of the biggest waves of drug patent expirations in ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |